BRIEF—Myricx Bio finds partner for ADC payloads

British start-up Myricx Bio, a spin out from Imperial College and the Francis Crick Institute, has inked an antibody license agreement with China’s Biocytogen Pharmaceuticals.

Myricx is working on novel cytotoxic payloads for antibody drug conjugates (ADCs), and the agreement will help it to develop and commercialize ADCs using antibodies derived from the RenMice platform.

The firm’s payloads are based on potent inhibitors of NMT, an enzyme that creates a specific lipid modification, a new approach in this therapeutic area.

Under the terms of the agreement, Biocytogen will carry out feasibility tests for ADCs created using these novel payloads in return for an upfront payment and further milestone payments of an undisclosed amount.